30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

NuVasive 2Q18 Revenue +8.5% vs. 2Q17 -

NuVasive (NUVA) reported 2Q18 revenue of US $281.6MM, +8.5% vs. 2Q17, and 1H18 revenue of $542.1MM, +6.6% vs. 1H17.

ORTHOWORLD estimates for segment sales and growth follow.

  2Q18  2Q17  $ Change  % Change 
 Spine $245.4  $221.6  $23.7  10.7% 
 Trauma $10.0  $8.8  $1.2  13.3% 
 Orthobiologics $26.3  $29.0  -$2.7  -9.4% 
Total  $281.6  $259.4  $22.2  8.5% 


  1H18  1H17  $ Change  % Change 
 Spine $469.5  $433.2  $36.3  8.4% 
 Trauma $18.6  $16.4  $2.3  13.8% 
 Orthobiologics $54.0  $58.8  -$4.9  -8.3% 
Total  $542.1  $508.4  $33.7  6.6% 


Revenue by geographic region:

  2Q18  1H18 
 U.S. $226.95  $440.25 
 Ex-U.S. $54.62  $101.83 

LOTS of information about FDA 510(k) cleared Pulse surgical automation! First, the revenue highlights.

Overall, 2Q revenue growth was driven by U.S. case volume, improvements in clinical services and solid ex-U.S. execution (particularly in Brazil and Japan). New technology introductions and an expanding surgeon base are supporting NuVasive’s ability to take market share globally.

NUVA’s U.S. hardware business was buoyed by a 7% case volume increase year over year, traction from the new Lateral Single-Position Surgery procedure and strong demand for products introduced in late 2017, such as RELINE posterior fixation, expandable implants and porous PEEK implants.

Of note, the Specialized Orthopedics division was called out with strong double-digit growth and a robust uptake of adult limb-lengthening.

Biologics faced a higher comp in the previous year; NUVA has adjusted to be more competitive and is recapturing lost accounts. A broader product offering—beyond Osteocel and toward synthetics, for example—is available. Improvement is expected in 2H18.

On to Pulse!

Pulse is the brand name for the foundation of hardware and software that supports a Surgical Intelligence “ecosystem” of neuromonitoring, surgical planning with artificial intelligence, rod bending, smart imaging, 2D/3D navigation and automation.

It is modular. Hospitals and ASCs can buy just the parts that they want. The navigation system is reportedly the first ever to be designed from scratch for spine. It is an open system, though the navigation will work best with NUVA implants. It will be priced lower than other robotic systems. NUVA plans more announcements about the automation aspect in 2019. (As we noted when reporting year-end revenue, the automation may or may not include a robotic aspect in the future.)

Pulse marks a “significant step in our evolution from a product-focused company to a systems-based company, committed to delivering end-to-end solutions for surgeons and hospital systems,” per CEO Gregory Lucier. NUVA will debut the system at NASS in September and begin taking orders, delivering to alpha customers first; commercial delivery is slated for 2Q19.

Sources: NuVasive, Inc.; ORTHOWORLD estimates

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.